Dr. Zhang on the Selection of Immunotherapy-Based Regimens in Metastatic RCC
Tian Zhang, MD, MHS, discusses the selection of first-line immunotherapy-based treatments for patients with metastatic renal cell carcinoma.
Source: onclive.com
Stay updated with breaking news from Vegf Tkis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tian Zhang, MD, MHS, discusses the selection of first-line immunotherapy-based treatments for patients with metastatic renal cell carcinoma.
A comprehensive overview of the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced renal cell carcinoma.